The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 25, 2021

Filed:

May. 22, 2017
Applicant:

Octapharma Ag, Lachen, CH;

Inventors:

Christoph Kannicht, Berlin, DE;

Stefan Winge, â„«rsta, SE;

Guido Kohla, Berlin, DE;

Barbara Solecka-Witulska, Berlin, DE;

Assignee:

OCTAPHARMA AG, Lachen, CH;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 38/37 (2006.01); C07K 14/745 (2006.01); C07K 14/755 (2006.01); A61P 7/04 (2006.01); C12N 15/62 (2006.01);
U.S. Cl.
CPC ...
A61K 38/37 (2013.01); A61P 7/04 (2018.01); C07K 14/745 (2013.01); C07K 14/755 (2013.01); C12N 15/62 (2013.01); A61K 38/00 (2013.01); C07K 2319/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/20 (2013.01); C07K 2319/31 (2013.01); C07K 2319/35 (2013.01);
Abstract

The invention relates to a glycosylated polypeptide comprising an amino acid sequence being identical or homologous to at least a fragment of a mammalian, preferably a human protein, wherein said glycosylated polypeptide contains one or more sialylated O-glycans and wherein the glycosylated polypeptide shows an increased binding affinity to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9 compared to the mammalian protein or fragment thereof. The invention further relates to composition comprising a first and a second polypeptide, wherein the first polypeptide is a glycosylated polypeptide containing one or more sialylated O-glycans and the second polypeptide contains an amino acid sequence homologous or identical to a second mammalian, in particular human protein, wherein compared to the second polypeptide the composition has an increased binding affinity to a SIGLEC selected from to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9.


Find Patent Forward Citations

Loading…